0
According to a report in a Chinese newspaper, China is planning to spend more than CNY 10 billion (US$1.5 billion) to support the development of new drugs between 2011 and 2016. Biotechnology was identified as one of seven emerging industries that China will use to spearhead the next big step in its economic development.
- INICIO
-
Genéricos
Novedades
- FDA approves generic teriparatide and levetiracetam
- US generics launch and approval for Dr Reddy’s and Lupin
- Five Chinese companies join UN’s MPP for Covid-19 medicines
- South Korean companies to make generic Bridion and COVID-19 drugs
Investigación
- Japan’s drug shortage crisis: challenges and policy solutions
- Saudi FDA drug approvals and GMP inspections: trend analysis
- Generic medications in the Lebanese community: understanding and public perception
- Community pharmacists’ understanding of generic and biosimilar drugs: Lebanon case study
General
- Crecimiento de medicamentos genéricos en Brasil y Venezuela
- EMA launches European shortages monitoring platform to tackle persistent medicine shortages
- Penetración de los medicamentos genéricos en México y Brasil
- FDA releases one-year progress report for the Generic Drug Cluster
-
Biosimilares
Novedades
- EMA recommends approval of three new biosimilars for diabetes and autoimmune conditions
- EMA recommends approval for pertuzumab and tocilizumab biosimilars
- FDA approves filgrastim biosimilar Filkri
- EC approves golimumab biosimilar Gotenfia and ranibizumab biosimilar Ranluspec
Investigación
- Biosimilar aflibercept (AVT06) pre-filled syringe promises safer, faster eye injections
- Un estudio de la OCDE no encuentra una relación directa entre las normas de publicidad y la adopción de biosimilares
- Alcanzar los objetivos ASG en el desarrollo farmacéutico
- What is the future for the US biosimilar interchangeability designation
General
- Biosimilars approved in Europe
- La SBR publica un posicionamiento sobre la intercambiabilidad segura entre biológicos originales y biosimilares
- Biosimilars approved in the US
- Samsung Bioepis wins Pyzchiva case; Regeneron patent rulings threaten foreign biosimilars
- MORE EDITORIAL SECTIONS
- Search
Post your comment